Bavarian Nordic To Take Prostvac Therapeutic Prostate Cancer Vaccine Into Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish firm won license for the therapy, once held by defunct Therion, in CRADA with NCI.
You may also be interested in...
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class
Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.